Original from: PR Newswire AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care a..

RealBio and Thermo Fisher Scientific Partner on IVD Quality Control Solutions On May 12 in Shanghai, RealBio signed a strategic agreement with Thermo Fisher Scientific to collaborate on co..

Original from: Co-Diagnostics Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic..

Original from: Natera Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as ..

Original from: PR Newswire - Labcorp's full test menu will be available through Epic's Aura platform - Integration builds on the successful deployment of Invitae genetic testing and accelerates acc..

Original from: Lucid Diagnostics Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:..

Original from: PR Newswire Cepheid, a Danaher company, announced today that it has received CE marking under the in vitro medical device regulation (IVDR) for the Xpert GI Panel. This multiplex PCR test ..

Original from: business news - Delivers the only FDA-cleared ChLIA testosterone testing portfolio with direct measurement of total testosterone, free testosterone, and sex hormone-binding globulin ..

Original from: Waters Corporation First Quarter 2026 Highlights - Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformanc..

Original from: Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and desig..

As of 30 April 2026, a total of 86 China-listed companies related to the In Vitro Diagnostics (IVD) sector had released their 2025 annual reports, including 61 companies primarily engaged in IVD businesses and 25 comp..

Sansure Biotech Partners with Tencent Health to Launch an AI Ecosystem for China Primary Healthcare On May 9, Sansure Biotech signed a strategic cooperation agreement with Tencent Health at..

3.3.2 Future Development of Blood Typing Instruments Working Party on Clinical Transfusion Management, Chinese Society of Blood Transfusion investigated blood transfusion departments of 2309 hospitals in differe..

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA).

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.